<DOC>
	<DOCNO>NCT00001628</DOCNO>
	<brief_summary>The renin angiotensin system ( RAS ) play important physiological pathophysiological role control blood pressure plasma volume . Inhibition RAS useful treatment hypertension , cardiac failure patient myocardial infarction . Several recent clinical trial angiotensin convert enzyme inhibitor ( ACEI ) show also reduce incidence myocardial infarction , mechanisms underlie anti-ischemic effect poorly understood . ACEI reduce angiotensin II synthesis prevent bradykinin degradation . Results ongoing study Cardiology Branch ( Protocol 95-H-0099 ) design investigate link ACEI vascular endothelium indicate ACEI improve peripheral endothelial function , effect partially mediate bradykinin . The current protocol design investigate whether beneficial effect ACEI peripheral endothelial function also due inhibition angiotensin II . The recent development selective angiotensin II type 1 ( AT1 ) receptor antagonist allow u specifically examine effect angiotensin II vasomotor activity .</brief_summary>
	<brief_title>The Role Angiotensin Type I Receptor Regulation Human Peripheral Vascular Function</brief_title>
	<detailed_description>The renin angiotensin system ( RAS ) play important physiological pathophysiological role control blood pressure plasma volume . Inhibition RAS useful treatment hypertension , cardiac failure patient myocardial infarction . Several recent clinical trial angiotensin convert enzyme inhibitor ( ACEI ) show also reduce incidence myocardial infarction , mechanisms underlie anti-ischemic effect poorly understood . ACEI reduce angiotensin II synthesis prevent bradykinin degradation . Results ongoing study Cardiology Branch ( Protocol 95-H-0099 ) design investigate link ACEI vascular endothelium indicate ACEI improve peripheral endothelial function , effect partially mediate bradykinin . The current protocol design investigate whether beneficial effect ACEI peripheral endothelial function also due inhibition angiotensin II . The recent development selective angiotensin II type 1 ( AT1 ) receptor antagonist allow u specifically examine effect angiotensin II vasomotor activity .</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Atherosclerosis</mesh_term>
	<mesh_term>Angiotensin II</mesh_term>
	<mesh_term>Angiotensinogen</mesh_term>
	<mesh_term>Angiotensin II Type 1 Receptor Blockers</mesh_term>
	<mesh_term>Angiotensin Receptor Antagonists</mesh_term>
	<criteria>Patients 18 year endothelial dysfunction require diagnostic cardiac catheterization . Normal volunteer patient undergoing catheterization normal coronary artery without risk factor atherosclerosis use control . No unstable angina . No significant leave main disease ( great 50 % stenosis ) . No recent myocardial infarction ( less 1 month ) . No pregnancy , lactation . No allergy losartan . No renal failure ( creatinine great 2.5 mg/dl ) . Ability withdraw ACE inhibitor .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 1999</verification_date>
	<keyword>Angiotensin Receptor Antagonist</keyword>
	<keyword>Atherosclerosis</keyword>
	<keyword>Blood Flow</keyword>
	<keyword>Endothelium</keyword>
	<keyword>Endothelial Dysfunction</keyword>
</DOC>